Company: EDSA
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001171843-25-003189
Chunk: 60

Company: Edesa Biotech, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 60
---

			)

			(3,538,982
			)

			Income tax expense

			800

			800

			800

			800

			Net loss

			(1,590,448
			)

			(1,861,331
			)

			(3,207,701
			)

			(3,539,782
			)

			Exchange differences on translation

			(63,731
			)

			(11,183
			)

			(45,075
			)

			(11,755
			)

			Net comprehensive loss

			$
			(1,654,179
			)
			 
			$
			(1,872,514
			)
			 
			$
			(3,252,776
			)
			 
			$
			(3,551,537
			)

			Weighted average number of common shares

			5,305,763

			3,192,688

			4,314,676

			3,160,179

			Loss per common share - basic and diluted

			$
			(0.30
			)
			 
			$
			(0.58
			)
			 
			$
			(0.74
			)
			 
			$
			(1.12
			)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

4

Edesa Biotech, Inc.

Condensed Interim Consolidated Statements of Cash Flows

			Six Months Ended 

			March 31, 2025

			March 31, 2024

			Cash flows from operating activities:

			Net loss

			$
			(3,207,701
			)
			 
			$
			(3,539,782
			)

			Adjustments for:

			Depreciation and amortization

			67,618

			90,428

			Share-based compensation

			147,836

			334,053

			Gain on loan forgiveness

			-

			(14,766
			)

			Changes in working capital items:

			Accounts and other receivable

			(